Am Fam Physician. 2024;109(6):578-579
Author disclosure: No relevant financial relationships.
RSVpreF (Abrysvo) is a respiratory syncytial virus (RSV) vaccine. It induces antibodies to the viral surface protein (protein F) that attaches the virus to host cells. RSVpreF is labeled for active immunization of individuals 60 years and older for the prevention of lower respiratory tract infection (LRTI). It is also labeled for use in pregnant individuals to prevent severe LRTI caused by RSV in infants in the first 6 months of life. Passive immunization occurs through transplacental transfer of maternal antibodies to infants.1 Nirsevimab-alip (Beyfortus) is an anti-RSV monoclonal antibody indicated for infants entering their first RSV season and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.2
| Drug | Dosage | Dose form | Cost of full course* |
|---|---|---|---|
| RSVpreF (Abrysvo) | One 0.5-mL intramuscular injection | Single-dosesyringe: 0.5 mL | $300 |
| Nirsevimab-alip (Beyfortus) | One 50-mg or 100-mg intramuscular injection or Two 100-mg intramuscular injections | Single-dose prefilled syringe: 50 mg per 0.5 mL 100 mg per 1 mL | $500 |
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
